SEC/FDA/FTC Regulatory Watch: E-Delivery, oral PCSK9 approval, and HSR penalties (July 13-19, 2026)

This issue covers 10 dated developments published or posted from July 13 through July 19, 2026. The SEC proposed default electronic delivery for a broad set of investor documents and brought new insider-trading and offering-misstatement cases; the FDA approved the first oral PCSK9 inhibitor, issued an animal-drug EUA, and posted warning letters; the FTC pursued HSR reporting, PBM, and supplement-advertising matters. The agency materials do not establish a causal share-price reaction, so the practical signals here are filing obligations, product access, transaction controls, and remedial work.

The SEC's broadest policy move this week is Regulation E-Delivery. The proposal would let covered entities deliver a wide range of regulatory information electronically without first obtaining affirmative consent, while preserving a recipient's ability to request paper. The covered material includes fund and issuer prospectuses, shareholder reports, proxy statements, trade confirmations, Form CRS disclosures, and Form ADV Part 2 brochures. 1

The proposed rule would replace the SEC's older guidance-based approach and would create a transition process for people currently receiving paper. Those recipients would receive two paper notices about the transition and the opt-out path. The proposal also would rescind the alternative method for registered investment companies to transmit shareholder reports and amend rules for proxy and tender-offer materials. 2

The comment period is 60 days after publication in the Federal Register, not 60 days from the SEC issue date. The SEC's comment file identifies File No. S7-2026-25, Release Nos. 33-11430, 34-105921, 39-2564, IA-6980, and IC-36252. Investor-relations, transfer-agent, fund-administration, and broker-dealer teams should inventory the documents they send, the evidence that delivery occurred, and the controls for paper requests before deciding whether to comment.

The week's enforcement releases add two different control failures.

On July 13, the SEC announced a settled action against Battle Motors and CEO Michael W. Patterson. The agency alleged that the company described 115 electric-vehicle purchase orders worth $30 million when it had purchase orders for eight vehicles worth about $2 million. It also alleged that Battle represented a dealer network of 180 dealers and 320 locations when it had 47 dealers and 156 locations. The statements were tied to a convertible-debt offering that raised $112.5 million from two investors. Battle and Patterson consented to final judgments without admitting the allegations, subject to court approval. 3

The practical issue for issuers is the evidence file behind sales pipelines, purchase orders, dealer counts, and investor presentations. A management estimate can become a securities-law problem when it is presented as an existing order or operating fact. Counsel should reconcile each headline metric to dated contracts, internal definitions, and the assumptions used in the offering materials.

On July 17, the SEC charged former Desktop Metal senior executive and director Ali El Siblani and three friends over alleged insider trading ahead of Desktop Metal's announcement that it would acquire ExOne at a premium. The SEC alleges that the friends built positions in ExOne securities after receiving material nonpublic information and sold after the announcement. It attributes alleged profits of $218,036 to Jamal Chammout, $218,082 to Ali Jawad, and $61,006 to Rabih Rakha. 4

El Siblani, Jawad, and Rakha agreed to proposed final judgments subject to court approval. The proposed terms include a $497,124 civil penalty for El Siblani, disgorgement and interest plus a civil penalty for Jawad, disgorgement and interest plus a civil penalty for Rakha, and a four-year officer-and-director bar for El Siblani. Chammout is charged in the complaint, which seeks relief against all defendants. The immediate compliance task is a review of deal-team access, personal-account monitoring, restricted lists, and evidence that tipper and tippee controls were applied before the public announcement.

Lipfendra gives Merck a once-daily oral alternative in a class previously available only as injectable therapies. FDA approved enlicitide as an adjunct to diet and exercise for adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia. The two placebo-controlled trials enrolled 3,207 adults on maximally tolerated statin therapy. FDA reported average Week 24 LDL-C reductions of 56% in the first trial and 59% in the familial-hypercholesterolemia trial. 5

For Merck, the regulatory work now shifts to launch execution: payer access, prescribing guidance, post-market surveillance, and the evidence needed for any comparative or cardiovascular-outcome claims. FDA's approval establishes the LDL-C indication and trial results; it does not by itself support claims about preventing heart attacks or strokes beyond the approved labeling.

The FDA also issued an EUA for Ivermectin Liquid for Horses, an oral solution sponsored by Alberta Vet Labs Ltd. The authorization covers short-term prevention of New World screwworm myiasis when the product is administered within 24 hours of birth or at initial wound care. It is not authorized to treat an existing infestation, is available only by prescription from a licensed veterinarian, and is not for species other than horses. FDA said the prevention window lasts no more than 24 hours and should be paired with measures such as bandaging, repellents, and fly control. 6

The warning-letter index added a useful quality-system signal on July 14, but the underlying letter dates are older. Spa De Soleil's July 8 letter describes 51 unexplained out-of-limit or out-of-specification water results between May 2024 and July 2025, including conductivity, total organic carbon, and gram-negative microorganism findings. FDA called for remediation of investigations, water-system design and validation, component testing, and a risk assessment for drug lots within expiry. 711

The same July 14 index posting included Nihon Kohden Digital Health Solutions' June 12 letter. FDA said a software change added a Silence Alarms function and a device-agnostic compatibility claim without the required new 510(k) submission. The agency warned that missed alarms or unvalidated interoperability could create patient risk and required a written response within 15 business days of receipt. 712

The FTC's largest dollar action this week concerns the Edwards Lifesciences acquisition of JC Medical from Genesis MedTech. The agency alleged that Edwards paid $115 million plus milestone payments for JC Medical, just below the $119.5 million size-of-transaction threshold in effect at the time, while also making a contemporaneous $25 million investment in Genesis. The FTC said the combined transactions met the threshold for mandatory HSR reporting. 8

The proposed final judgment would require Edwards to pay $10 million and Genesis $2 million. It would also require Edwards to give advance written notice before acquiring an interest in a company that sells, is testing, or has an FDA Investigational Device Exemption for a transcatheter aortic valve replacement device for aortic regurgitation. Edwards would have to maintain an antitrust compliance program. The Department of Justice filed the complaint and proposed judgment for the FTC; the order has the force of law only after the district court approves and signs it. The parties deny wrongdoing, and the settlement is not an admission or finding of liability.

The Caremark announcement extends the FTC's PBM enforcement campaign. The agency announced a July 14 settlement resolving its antitrust case against a second drug middleman. PBMs, plan sponsors, and pharmacy-contract teams should review the settlement's business-practice terms and compare their insulin-pricing, reimbursement, and disclosure practices against the required changes. 9

The immediate action for PBMs, plan sponsors, and pharmacy-contract teams is to preserve pricing and reimbursement records, map any insulin-related arrangements, and compare disclosure and contracting practices against the final settlement. The FTC's announcement is a regulatory signal, not a finding that every similar arrangement violates the law.

On July 15, the FTC approved a final order against Vanilla Chip LLC, doing business as TruHeight, and two principals. The order followed allegations that the company used deceptive and unsubstantiated advertising for supplements marketed to children and teens. The FTC's release says the respondents must pay $750,000 and may not make false or unsubstantiated advertising claims. 10

Health, wellness, and creator-economy marketers should keep a claim-by-claim evidence file for height, growth, safety, and outcome representations, including the support for testimonials and the audience's age. A disclaimer does not cure a claim that the underlying evidence cannot support.

The week's pattern is operational rather than purely punitive. The SEC is asking firms to redesign delivery and control information around offerings and deals; the FDA is pairing product access with evidence and quality-system obligations; and the FTC is treating transaction structure and health claims as compliance facts that must be documented before launch or closing.